RU58841 and High-Strength Minoxidil: The Regulatory Facts

Factual summary compiled from public regulatory sources. Not medical advice, not a recommendation, and not instructions for use. No dosing appears anywhere on this site, nothing here is for sale, and this page carries no commercial relationship. How this page is sourced.

RU58841 and topical minoxidil — at a glance. Every row restates a statement made in full below.

RU58841 approval	None, in any country; development was discontinued
RU58841 evidence	No published controlled human trials; long-term safety unstudied
Minoxidil 2% and 5%	FDA-approved over the counter for pattern hair loss
Minoxidil 10%+	Not an FDA-approved formulation
Evidence-backed options	Topical minoxidil and finasteride

RU58841 status

RU58841 is an experimental topical antiandrogen originally investigated decades ago and never brought to market. It has no FDA approval in any country, and there are no published controlled human trials establishing its efficacy or safety. Development was discontinued; the compound survives only as a gray-market research chemical. Long-term human safety is entirely unstudied.

Minoxidil: what's actually approved

Topical minoxidil is FDA-approved over the counter at 2% and 5% concentrations for pattern hair loss, and it's one of only two treatments with that approval. Higher concentrations — 10% and above — are not FDA-approved formulations. They're produced by compounding pharmacies or sold online. Published dermatology literature indicates that increasing concentration above 5% yields limited additional benefit for many users while raising the incidence of side effects including scalp irritation, unwanted facial hair growth, and systemic absorption effects such as fluid retention and increased heart rate.

Why the distinction matters

Approved 5% minoxidil and unapproved 10% compounded formulations are legally and clinically different products. Only the former has been reviewed for safety and efficacy at that strength.

The evidence gap

For hair loss specifically, the treatments with actual regulatory approval and controlled trial data are topical minoxidil and finasteride. Everything else in this space — including RU58841 — is operating without that evidence base. A dermatologist is the appropriate person to discuss options with.

Last reviewed 2026-07-28 · how this page is sourced